OPEN ACCESS
PEER-REVIEWEDPotential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis
Garima Sharma1,
, D.S. Rathore1
1Department of Biotechnology, Govt. Kamla Raje PG (Autonomous) College, Gwalior (M.P.) India
Abstract
Nutraceuticals is a broad umbrella term that is used to describe any product derived from food sources with extra health benefits in addition to the basic nutritional value of that food. Over the years nutraceuticals have attracted considerable interest due to their potential nutritional, safe and therapeutic effects in a variety of chronic and life style related diseases like coronary blockage, diabetes and osteoarthritis. Osteoarthritis, better considered as a wear and tear of joint is a result of gradual deterioration of underlying cartilage tissue. The disease results in joint pain, stiffness and its long term effect leads to functional impairment. The current treatment modalities of OA include physical, pharmacological and surgical interventions. Use of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, corticosteroids and hyaluronic injections have proved significantly effective in pain relief and symptomatic management of this disease however their prolonged use have proven side effects on kidney, heart and liver functioning. The surgical methods like total joint arthroscopy, joint debridement, joint irrigation etc. are employed in severe disease state however recovery and post surgical complications are inevitable. In this view focus is being shifted on the use of alternative therapies and nutritional supplements as pain relieving and cartilage protective agents. In the past 3-4 decades significant research has been conducted on the clinical and in vitro testings of nutraceuticals like Glucosamine, Chondroitin sulfate, Hyaluronic acid and others on osteoarthritic subjects and tissues. A large number of dietary supplements are used for a long time for pain relief like cod liver oil for arthritic patients and nowadays as many as one third of suffering populations is using them to improve their clinical condition. The common food sources of these compounds are spinach like leafy vegetables, shark shell, skinned meat etc. Some of the studies have suggested that the efficacy of these nutritional compounds in joint pain relief is equal to non steroidal antiinflammmatory drugs however their onset action is slow. One of the most important limitations associated with their use in treatment of joint related disease is that their clinical efficacy and trials are still lacking. Since nutraceuticals are marketed in a variety of forms like food supplements, injections and powders which have made their effect nonspecific and uncontrollable. In this paper we have covered the results of studies on three well established nutraceuticals (Glucsamine, Chondroitin and Hyaluronic acid) as joint protectors especially in two large weight bearing joints of the body i.e. knee and hip. The results of the studies have indicated that nutraceuticals could represent good alternative means of management of OA however further controlled clinical studies are required for differentiating the effect of purified compound and dose with that of whole food source.
Keywords: Nutraceuticals, Osteoarthritis, Chondroitin, Glucosamine, Hyaluronic acid
Received April 20, 2015; Revised May 29, 2015; Accepted June 29, 2015
Copyright © 2015 Science and Education Publishing. All Rights Reserved.Cite this article:
- Garima Sharma, D.S. Rathore. Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis. Biomedical Science and Engineering. Vol. 3, No. 1, 2015, pp 23-29. https://pubs.sciepub.com/bse/3/1/5
- Sharma, Garima, and D.S. Rathore. "Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis." Biomedical Science and Engineering 3.1 (2015): 23-29.
- Sharma, G. , & Rathore, D. (2015). Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis. Biomedical Science and Engineering, 3(1), 23-29.
- Sharma, Garima, and D.S. Rathore. "Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis." Biomedical Science and Engineering 3, no. 1 (2015): 23-29.
| Import into BibTeX | Import into EndNote | Import into RefMan | Import into RefWorks |
At a glance: Figures
1. Introduction
Nutraceuticals are the products isolated or purified from foods and have beneficial role in promotion of health by prevention and treatment of a disease. The term was first coined by Dr. Stephen. Word Nutraceutical is a combination of ‘Nutrition’ and ‘Pharmaceutical’. The advantages of nutraceuticals are their vast availability, no side effects and possibility of self medication [1]. Two major categories of nutraceuticals are phytochemicals and antioxidants. There are a wide variety of phytochemicals like carotenoids from carrot which provide protection from diseases such as cancer, diabetes, heart disease, and hypertension. Antioxidants are present in many organic acids and minerals obtained from plants. Other than these two, many nutraceuticals are animal products like cod liver oil, fishes and others. All these are useful in supplying building blocks of extracellular matrix products of many tissues and prevent cellular damage due to free radicals accumulation. Thus helpful in preventing chronic diseases like osteoarthritis, liver cirrohsis and others [2].
Osteoarthritis (OA) is one of the most prevalent joint disabling disease affecting mainly the elderly (nearly 50% population above 50 years of age and 85% of above 65 years of age worldwide) [3]. The disease is an outcome of gradual deterioration of the articular cartilage tissue due to wear and tear of it. It results in impaired joint motion, severe pain and stiffness and ultimately leads to joint disability (Figure 1). Its high prevalence and its moderate-to-severe impact on daily life pose a significant public health problem [4].
Download as
OA has no cure and currently focus is on treatment modalities which relieve the symptoms like joint pain and stiffness. For example, analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly prescribed to OA patients, generally decrease pain and improve function, but have no demonstrated beneficial effect on chondroprotection or OA disease prevention and modification [5]. A prolonged use of these pharmacological agents to relieve OA symptoms is associated with substantial gastrointestinal, renal, and cardiovascular side effects [5, 6]. In the current scenario interest has been generated in utilizing nutraceuticals as chondroprotecvive agents due to their safety profile and potential in disease modification. The role of proteins and amino acids, fatty acids (e.g., omega-3), vitamins, and certain minerals in providing building blocks for biological processes and support the structure and function of joints is long established [7, 8, 9, 10].
Various natural compounds present in fruits, teas, spices, wine, and vegetables have shown remarkable potential in modifying OA disease and symptoms. The molecular mechanism is though not clearly known, the effect is believed to be due to their anti-inflammatory, anti-catabolic and antioxidative effects [11, 12]. A study has suggested that about 47% of adults in America and Japan consume non-prescribed alternative medications (including food supplements and nutraceuticals) for OA management and it has industry worth 86 billion$ annually in USA [13]. However there are various limitations associated with the use of nutraceuticals in management of osteoarthritis and other diseases like their clinical testings and regulations are not as stringent as pharmaceuticals, majority of them are not regulated by FDA, their bioavailability is lower and effect may be attributed to that of a placebo as their molecular action is not very clear.
Consequently, there is a timely and urgent need for OA therapy which can improve disease symptoms, prevent its progression and is safe for clinical use over long periods of time. This review has provided an imminent view on the efficacy and mechanism of action of commonly used nutraceuticals like Chondroitin sulfate, Glucosamine sulfate and Hyaluronic acid and has discussed recent experimental and clinical data on their effects in management of osteoarthritis with special reference to knee and hip joint.
2. Current Modalities for Management of Osteoarthritis
The primary management of OA is largely based on the alleviation of symptoms and to provide relief to the patient. However the goals of OA therapy are gradually being expanded beyond the current concept of only “pain relief/ joint preservation” to:
• interfere with the induction of cartilage degrading mechanisms due to injury,
• restore normal cartilage and joint homeostasis,
• arrest disease progression in osteoarthritic and post osteoarthritic states,
• revert cartilage damage and restore its normal structure and function.
Current recommendations for the management of OA include a combination of nonpharmacological interventions (weight loss, education programs, exercise etc) and pharmacological treatments (paracetamol, nonsteroidal anti-inflammatory drugs [NSAIDs]) [14, 15]. In this context, there is a need for safe and effective alternative treatments while the absence of any cure reinforces the importance of prevention. Some of the promising avenues in achieving progress towards cartilage regeneration include viscosupplementation (using hyaluronic acid), disease modifying drugs, and use of NUTRACEUTICALS (like chondroitin sulfate hyaluronic acid and glucosamine) [3, 16, 17].
1. Dietary Supplements including botanicals Vitamins, co-enzymes, minerals
2. Functional Foods Oats, bran, Psyllium, lignin's, Prebiotics, Omega-3 milk, Canola oil,
3. Medicinal Foods: Transgenic cows and lactoferrin for immune enhancement, Transgenic plants for oral vaccination against infectious diseases.
Among these vitamins, co enzymes and some animal and plant products have been studied for pain relief in osteoarthritis for last three decades. The efficacy of fish oils (e.g. cod liver oil) in the diet has been demonstrated in several clinical trials, animal feeding experiments and in vitro models that mimic cartilage destruction in arthritic disease [18, 19, 20]. Other than this, there is some evidence of use of other nutraceuticals, such as green tea, herbal extracts, chondroitin sulphate and glucosamine preparations in arthritic joint [13, 16].
2.1. GlucosamineGlucosamine is a naturally occurring substance found in the synovial fluid around our joints. It is naturally present in animal bones, bone marrow, shellfish and fungi (Figure 2). Glucosamine plays a vital role in building cartilage and is commonly consumed as a supplement by people with arthritis, especially osteoarthritis. Glucosamine is vital for building cartilage because it is a precursor for glycosaminoglycans which is a major component of joint cartilage. With aging, glucosamine levels go down, which can lead to eventual joint deterioration.
Glucosamine can come in different forms, including like glucosamine sulfate, glucosamine hydrochloride and N-acetyl-glucosamine. Although similar, the three forms may not have the same effect when used as dietary supplements.
Most studies that have examined the potential health benefits of glucosamine have focused on glucosamine sulfate (GS).
Download as
Glucosamine has also been used as skin cream for pain relief in arthritis however its effect is not very clear as there is no evidence that glucosamine is absorbed by the skin [21].
According to the National Center for Complementary and Alternative Therapy, a 2007 National Health Interview survey found that 17.7% of adults in the USA regularly took some type of dietary supplement. Of those people, 19.9% took glucosamine, the second most popular dietary supplement after fish oil/omega (37.4%) [22].
Several scientific studies have shown that glucosamine supplements may help patients with osteoarthritis (OA), especially of the hip or knee [23, 24, 25, 26, 27]. The effects of glucosamine are manifested by:
• Reduction in osteoarthritis-related pain
• Improved function in patients with knee or hip osteoarthritis
• Reduced stiffness and swelling in the joints
• Continued to provide relief of symptoms up to 3 months after patients stopped treatment.
2.1.1. Molecular Mechanism for Action of Glucosamine Sulfate in OA
The mechanism of action of glucosamine in humans is largely unknown. However being a part of the cartilage matrix in joint tissues; its administration is believed to cause symptomatic relief for OA sufferers by supplying the components for cartilage repair and thus improving pain and disability.
In some recent studies it has been demonstrated in animal models that glucosamine has an anti-inflammatory effect via the reduction of nuclear factor kappa beta induced by interleukin-1 (IL-1) [28, 29]. A few studies in humans also have revealed that glucosamine HCl reduces IL-1 stimulated production of catabolic enzymes and inflammatory markers such as prostaglandin E2 by chondrocyte and synovial cells harvested from surgical specimens removed from patients with OA [30, 31].
In another recent study on a model of spontaneous osteoarthritis in Harley guinea pigs shows that long-term oral administration of glucosamine sulfate reduces the destruction of cartilage and upregulation of MMP-3 mRNA [32]. Another study suggested that glucosamine can prevent cytokine-induced demethylation of a specific CpG site in the IL1β promoter and cause decreased expression of IL1β [33]. It was suggested that since glucosamine inhibits both anabolic and catabolic genes, the therapeutic effects of glucosamine might be due to anticatabolic activities, rather than due to anabolic activities. In some clinical studies effect of a long term dose of oral GS is monitored and found to have a more decreased Lequesne’s index to those receiving a placebo and in comparison to chondotin sulfate and manganese ascorbate [34, 35, 36].
2.2. Chondrotin Sulfate (CS)Chondroitin sulfate (CS) is a major component of the extracellular matrix of many connective tissues including articular cartilage. Chondroitin sulfate (CS) is one of the natural glycosaminglycans (GAG) composed of the alternating sugars D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc) (Figure 3). CS is widely distributed in matrix where it forms an essential component of proteoglycans by covalent links with proteins [37]. Commonly referred as a “symptomatic slow-acting drug in OA” (SySADOA), CS is widely used in the management of OA patients [38]. It is often used in combination with other products, including manganese ascorbate, glucosamine sulfate, glucosamine hydrochloride, or N-acetyl glucosamine.
Download as
2.2.1. Molecular Mechanism for Action of Chondroitin Sulfate in OA
Chondroitin Sulfate is part of a protein molecule that helps give cartilage its elastic properties and is thought to have an anti-inflammatory effect, which can help to reduce the painful swelling in the joints that occurs when the exposed bones in the joint rub together. In addition, chondroitin sulfate may also help slow the breakdown of cartilage and help restore cartilage growth to better cushion the joints [39]. Clinical trials have shown that CS reduces pain and improves articular function, reduces joint swelling and effusion, and prevents joint space narrowing of the knee more effectively than Placebo [38, 40, 41].
CS has a complex role in reducing pain and swelling in joints which may be explained by an anti-inflammatory effect of it, mediated by diminishing the expression of phospholipase A2 (PLA2) [42], of cyclooxy genase-2 (COX-2), and the concentrations of prostaglandin E2 (PGE2) [43, 44]. CS is also known to reduce the concentrations of pro-inflammatory cytokines, such as TNF-a [45] and IL-1b [46] and systemic and joint concentrations of NO [47] and of reactive oxygen species (ROS) [45].
Various studies in animal models and in humans have supported that CS has beneficial effect on both articular cartilage and synovial membrane [24, 48, 49, 50]. However the mechanism of action underlying the reduction of synovitis by CS and other glycosaminoglycans remains incompletely characterized.
CS also has in-vitro anti-inflammatory properties and its addition to synoviocytes culture during the stationary phase of growth stimulates hyaluronate synthesis which is suggested to reduce inflammation in articular tissues [51, 52, 53].
In a significant GAIT study (Glucosamine/ chondroitin arthritis Intervention trial) conducted by Sawitzke et al 2008, the individual and combined effects of CS and GS were monitored in a large no of human subjects [54]. The results showed potential effect of these compounds only in higher grade of disease. In some cell culture studies, CS has been shown to have anti-inflammatory and anti-catabolic properties on chondrocytes [55].
In a previous study conducted by one of the authors of this paper, CS supplementation has shown an improved chondrocytes morphology and collagen synthesis along with cyclic pressurization protocol in alginate seeded culture of goat chondrocytes [56].
Another study has shown downregulation of m-RNA of inflammatory mediators and matrix degrading enzymes on bovine cartilage explants with glucosamine and chondroitin sulfate treatment [57].
2.3. Hyaluronic AcidHyaluronic acid (HA) is a nonsulfated glycosaminoglycan distributed widely in connective tissues like cartilage (Figure 4). It is a naturally occurring substance found in the synovial fluid which acts as a lubricant to enable bones to move smoothly over each other and as a shock absorber for joint loads.
Download as
HA is responsible for the viscoelastic quality of synovial fluid that acts as both a lubricant and shock absorber [58]. In synovial fluid, HA coats the surface of the articular cartilage and shares space deeper in the cartilage among collagen fibrils and sulfated proteoglycans (PGs). In this respect, HA probably protects the cartilage and blocks the loss of PGs from the cartilage matrix into the synovial space, maintaining the normal cartilage matrix [58].
Injection of hyaluronic acid into arthritic knee joint with aim of pain relief is known as ‘viscosupplementation’.
Viscosupplementation has been shown to relieve pain in many patients who have not responded to other nonsurgical methods [59, 60]. The technique was first used in Europe and Asia, and was approved by the U.S. Food and Drug Administration in 1997. Several preparations of hyaluronic acid are now commercially available.
In a significant study intraarticular hyaluronic acid injections were highly effective in improving resting and walking pain in patients with osteoarthritis of the knee [61]. These data support the potential role of intraarticular hyaluronic acid as an effective long-term therapeutic option for patients with osteoarthritis of the knee.
In some of the recent studies attempts are made to repair cartilage defects using injection of a variety of hydrogels like bone marrow concentrate, hyaluronic acid and fibrin and encouraging results are found [62, 63].
2.3.1. Molecular Mechanism for Action of Hyaluronic Acid in OA
In acute and chronic inflammatory processes of the joint, the size of HA molecules decreases at the same time as the number of cells in the joint space increases [58]. Administration of exogenous HA in knee cultured cells facilitate the production of new HA synthesis in a dose dependent manner [64].
HA also has a role in nociception i.e. affecting the nerve impulse and nerve sensitivity thus causing a relief in pain as indicated in some of the studies [65, 66]. Exogenous HA has noted effects on the extracellular matrix, inflammatory mediators, and immune cells as reported in in vitro studies. The influence of HA on these factors may contribute to overall cartilage protection in OA.
In vitro experiments indicate that HA administration can enhance the synthesis of extracellular matrix proteins, including chondroitin and keratin sulfate, and PGs in chondrocytes [67, 68].
HA has also been shown to suppress cartilage damage by fibronectin fragments in vitro and in vivo. These fragments of fibronectin are responsible for increased levels of Matrix metlloproteases and thus suppress PG synthesis [69, 70]. Studies have also suggested role of hyaluronan on inflammatory mediators including cytokines, proteases and their inhibitors, and prostaglandins that may translate into cartilage protection. In vitro studies showed that HA alters the profile of inflammatory mediators such that the balance between cell matrix synthesis and degradation is shifted away from degradation [71, 72, 73, 74, 75].
3. Natural Food Sources of Glucosamine, Chondroitin Sulfate and Hyaluronic Acid
Glucosamine is made in the body from glucose (a sugar) and the amino acid glutamine. Food sources containing high concentrations of glutamine include raw parsley and spinach. Glucosamine sulfate is found in the largest amounts in cartilage-containing products like those harvested from shark and bovine sources. It is widely distributed in the animal world and humans have been ingesting glucosamine in the form of cartilage (“gristle”) for thousands of years. It’s also a natural component of chitin, a major structural component of the hard shells of clams, oysters, and other shellfish.
The significant source of chondroitin sulfate is also animal cartilage. The major commercially available source is bovine, porcine (pork), chicken and shark cartilage.
Animal products are considered by far to be the best dietary source of hyaluronic acid especially in tissues like meats with large amounts of skin, bones and other connective tissues, beef or pork. Most vegetables are also good sources of hyaluronic acid especially with starchy roots and tubers like potatoes, sweet potatoes, peas and carrots. Brown rice, soyabean is rich in hyaluronic acid. In addition to meat and vegetables, seeds, nuts, and fruit are all good hyaluronic acid food sources. Foods that is rich in magnesium increases hyaluronic acid absorption like apples, tomatoes, avocados, strawberries, and pineapples. Other foods that may contain or help in the production of hyaluronic acid are pumpkin seeds, yeast, and peanuts.
4. Conclusion
Numerous studies across the world have supported the use of nutraceuticals for relief in clinical symptoms of osteoarthritis and allied diseases. These nutraceuticals not only improve the quality of life in elderly population but also supports the nonsurgical nonpharmacological intervention in osteoarthritis. The strongest data in combating the onset of these symptoms/diseases supports use of supplements of glucosamine, chondroitin sulfate and hyaluronic acid. According to the National Institutes of Health, glucosamine effectively relieves pain, swelling and stiffness in people with this chronic and debilitating condition. Its benefits have been most conclusively demonstrated for people with mild to moderate forms of osteoarthritis affecting the knees. Despite limited availability in natural food sources of glucosamine and chondroitin, some products have been fortified to contain medicinally active quantities of the compound. The potential use of these natural therapies in preventing or minimizing the debilitating effects of osteoarthritis could be worth a try. The clinical effects of glucosamine, chondrotin sulfate and Hyaluronic acid on pain associated with OA of the knee and hip joints are probably mediated by several factors. In vitro and in vivo studies indicate that these factors can contribute in synthesis of extracellular matrix of cartilage, suppress pain mediators and inflammation and cause relief. However studies related with the efficacy of these compounds in pure form as well as food products, concentration dependent role and their combinatorial effects are still needed.
Acknowledgements
The authors would like to thank the Principal of Govt. Kamla Raja Girls PG College Gwalior for providing necessary infrastructure and facilities for the above work.
Statement of Competing Interest
The authors have no competing interest.
References
| [1] | Chaturvedi S., Sharma P.K., Garg V.K. “Role of Nutraceuticals in Health Promotion”. Int J PharmTech Res 3 (1) 442-44, 2011. | ||
 In article | |||
| [2] | Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E. “Nutraceuticals: Do they represent a new era in the management of osteoarthritis?—A narrative review from the lessons taken with five products”. Osteoarthr. Cartilage. 19:1-21, 2011. | ||
| In article | View Article PubMed | ||
| [3] | Frech T.M., Clegg D.O. “The utility of nutraceuticals in the treatment of osteoarthritis”. Curr Rheum Rep 9 (1) 25-30, 2007. | ||
| In article | View Article PubMed | ||
| [4] | Yelin E “The economics of OA”. In Osteoarthritis. Brandt K.D., Doherty M., Lohmander L.S. (eds) Oxford: Oxford University Press: 17-21, 2003. | ||
| In article | |||
| [5] | Cheng D.S., Visco C.J. Pharmaceutical therapy for osteoarthritis. PM&R. 2012;4:S82-S88. | ||
| In article | View Article PubMed | ||
| [6] | Patrignani P., Tacconelli S., Bruno A., Sostres C., Lanas A. “Managing the adverse effects of nonsteroidal anti-inflammatory drugs”. Exp. Rev. Clin. Pharm. 4,605-21, 2011. | ||
| In article | View Article PubMed | ||
| [7] | Guimaraes A.G., Xavier M.A., de Santana M.T., Camargo E.A., Santos C.A., Brito F.A., Barreto E.O., Cavalcanti S.C., Antoniolli A.R., Oliveira R.C. “Carvacrol attenuates mechanical hypernociception and inflammatory response”. Naunyn. Schmiedebergs. Arch. Pharmacol. 385,253-263, 2012. | ||
| In article | View Article PubMed | ||
| [8] | Guimaraes A.G., Oliveira G.F., Melo M.S., Cavalcanti S.C., Antoniolli A.R., Bonjardim L.R., Silva F.A., Santos J.P., Rocha R.F.. “Bioassay-guided evaluation of antioxidant and antinociceptive activities of carvacrol.” Basic Clin. Pharmacol. Toxicol. 107, 949-957, 2010. | ||
| In article | View Article PubMed | ||
| [9] | Cavalcante Melo F.H., Rios E.R., Rocha N.F., Cito Mdo C., Fernandes M.L., De Sousa D.P., De Vasconcelos S.M., De Sousa F.C. “Antinociceptive activity of carvacrol (5-isopropyl-2-methylphenol) in mice. “ J. Pharm. Pharmacol. 64, 1722-29, 2012. | ||
| In article | View Article PubMed | ||
| [10] | Henrotin Y., Clutterbuck A.L., Allaway D., Lodwig E.M., Harris P., Mathy-Hartert M., Shakibaei M., Mobasheri A. “Biological actions of curcumin on articular chondrocytes.” Osteoarth. Cartilage. 18, 141-149, 2010. | ||
| In article | View Article PubMed | ||
| [11] | Shen C.L., Smith B.J., Lo D.F., Chyu M.C., Dunn D.M., Chen C.H., Kwun I.S. “Dietary polyphenols and mechanisms of osteoarthritis”. J. Nutr. Biochem. 23, 1367-1377, 2012. | ||
| In article | View Article PubMed | ||
| [12] | Daniel J. Leong Marwa Choudhury, David M. Hirsh, John A. Hardin, Neil J. Cobelli, Hui B. Sun. “Nutraceuticals: Potential for Chondroprotection and Molecular Targeting of Osteoarthritis”. Int J Mol Sci. 14(11) 23063-23085, 2013. | ||
| In article | View Article PubMed | ||
| [13] | Akhtar N., Haqqi T.M. “Current nutraceuticals in the management of OA: a review” Ther Adv Musculoskelet Dis. 4 (3) 181-207, 2012. | ||
| In article | View Article PubMed | ||
| [14] | Jordan K.M., Arden N.K., Doherty M. “EULAR Recommendations 2003: an evidence based approach to the management of knee OA: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials” Ann Rheum Dis 62, 1145-55, 2003. | ||
| In article | View Article PubMed | ||
| [15] | Ramsey S.D., Spencer A.C., Topolski T.D., et al. “Use of alternative therapies by older adults with osteoarthritis”. Arthritis Rheum 4, 222-27, 2001. | ||
| In article | View Article | ||
| [16] | Ragle R.L., Sawitzke A.D. “Nutraceuticals in the management of osteoarthritis: a critical review”. Drugs Aging 29 (9), 717-31, 2012. | ||
| In article | View Article PubMed | ||
| [17] | Reginster J.Y., Neuprez A., Lecart M.P. “Role of glucosamine in the treatment for osteoarthritis”. . Rheum Int 32 (10) 2959-67, 2012. | ||
| In article | View Article PubMed | ||
| [18] | Gupta V.K., Zafer Z.K., Ahmad M. “The Concomitant Consumption of Cod Liver Oil Causes a Reduction in the Daily Diclofenac Sodium Usage in Rheumatoid Arthritis Patients: A Pilot Study”. J Clin Diagn Res 7(7) 1347-51, 2013. | ||
| In article | View Article | ||
| [19] | Cleland L. G., James M. J., Proudman S. M. “Fish Oil: What The Prescriber Needs To Know”. Arth Res and Therapy. 8, 202, 2006. | ||
| In article | View Article PubMed | ||
| [20] | James M., Proudman S., Cleland L. “Fish Oil and Rheumatoid Arthritis: Past, Present and Future”. Proc Nutr Soc 69(3), 316-23, 2010. | ||
| In article | View Article PubMed | ||
| [21] | National Institutes of Health. Glucosamine sulfate. November 12th 2013. | ||
| In article | |||
| [22] | National Center for Complementary and Alternative Therapy. Using Dietary Supplements Wisely November 12th 2013. | ||
| In article | |||
| [23] | Chard J, Lohmander S, Smith C. et al. “Osteoarthritis of the knee”. Clin Evid 14, 1506-22, 2005. | ||
| In article | PubMed | ||
| [24] | Clegg D.O. “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.” New Eng. J. Med 354 (8) 795-808, 2006. | ||
| In article | View Article PubMed | ||
| [25] | Felson D.T. “Chondroitin for Pain in Osteoarthritis”. Annal Int. Med. 146: 611-12, 2007. | ||
| In article | View Article | ||
| [26] | Fransen M, Agaliotis M, Nairn L, et al. “Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomized placebo-controlled clinical trial evaluating single and combination regimens”. Annal Rheum Dis 74(5), 851-8, 2015. | ||
| In article | View Article PubMed | ||
| [27] | McAlindon T.E., Bannuru R.R., Sullivan M.C “OARSI guidelines for the non-surgical management of knee osteoarthritis”. Osteoarth. Cartil. 22: 363-88, 2014. | ||
| In article | View Article PubMed | ||
| [28] | Gouze J.N., Bianchi A., Becuwe P. “Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level and by inhibiting the NF-κB pathway”. FEBS Lett 510, 166-70, 2012. | ||
| In article | View Article | ||
| [29] | Gouze J.N., Gouze E., Popp M.P. “Exogenous glucosamine globally protects chodrocytes from the arthritogenic effects of IL-1β” Arthritis Res Ther. 8, R173, 2006. | ||
| In article | View Article PubMed | ||
| [30] | Nakamura H., Shibakawa A., Tanaka M. “Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis”. Clin Exp Rheumatol. 22, 293-99, 2004. | ||
| In article | PubMed | ||
| [31] | Uitterlinden E.J., Jahr H., Koevoet J.L. “Glucosamine decreases expression of anabolic and catabolic genes in human OA cartilage explants” Osteoarth. Cartilage. 14, 250-57, 2006. | ||
| In article | View Article PubMed | ||
| [32] | Taniguchi S., Ryu J., Seki M. “Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs”. J Orthop Res. 30(5), 673-78, 2011. | ||
| In article | View Article PubMed | ||
| [33] | Imagawa K., Andres M.C., Hashimoto K... “The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis”. Biochem Biophys Res Commun 405(3), 362-67, 2011. | ||
| In article | View Article PubMed | ||
| [34] | Setnikar I., Palumbo R., Canali S. “Pharmacokinetics of glucosamine in man” Arzneimittelforschung 43 (10), 1109-13, 1993. | ||
| In article | PubMed | ||
| [35] | Leffler C.T., Philippi A.F., Leffler S.G.. “Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study”. Mil Med 164 (2), 85-91, 1999. | ||
| In article | PubMed | ||
| [36] | Rindone J.P., Hiller D., Collacott E. “Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee”. West J Med. 172(2), 91-4, 2000. | ||
| In article | View Article PubMed | ||
| [37] | Dudhia J. “Aggrecan, aging and assembly in articular cartilage”. Cell Mol Life Sci 62 (19-20), 2241-56, 2005. | ||
| In article | View Article PubMed | ||
| [38] | Uebelhart D., Malaise M., Marcolongo R. “Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo”. Osteoarth Cartil 12: 269-76, 2004. | ||
| In article | View Article PubMed | ||
| [39] | Deal, C.L. “Neutraceuticals as Therapeutic Agents in Osteoarthritis.” Rheumatic Disease Clinics of North America. 25 (2), 379-95, 1999. | ||
| In article | View Article | ||
| [40] | Mazieres B, Combe B, Phan Van A, Tondut J, Grynfeltt M. “Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study”. J Rheumatol 28, 173-81, 2001. | ||
| In article | PubMed | ||
| [41] | Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O’Dell J.R., Hooper M.M.l. “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.” N Engl J Med 354, 795-808, 2006. | ||
| In article | View Article PubMed | ||
| [42] | Ronca F., Palmieri L., Panicucci P., Ronca G.. “Anti-inflammatory activity of chondroitin sulfate”. Osteoarthritis Cartilage 6 (Suppl A), 14-21, 1998. | ||
| In article | View Article | ||
| [43] | Chan P.S., Caron J.P., Orth M.W. “Effect of glucosamine and Chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants”. Am J Vet Res 66, 187-6, 2005. | ||
| In article | View Article | ||
| [44] | Orth M.W., Peters T.L., Hawkins J.N. “Inhibition of articular cartilage degradation by glucosamineeHCl and chondroitin sulphate.” Equine Vet J Suppl 224-9, 2002. | ||
| In article | PubMed | ||
| [45] | Campo G.M., Avenoso A., Campo S., Ferlazzo A.M., Altavilla D., Calatroni A. “Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats”. Arthritis Res Ther 5:R122-131, 2002. | ||
| In article | View Article PubMed | ||
| [46] | Chou M.M., Vergnolle N., McDougall J.J., Wallace J.L., Marty S., Teskey V. “Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis”. Exp Biol Med (Maywood) 230, 255-62, 2005. | ||
| In article | |||
| [47] | Chan P.S., Caron J.P., Rosa G.J., Orth M.W. “Glucosamine and Chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants”. Osteoarthritis Cartilage 13,387-94, 2005. | ||
| In article | View Article PubMed | ||
| [48] | Goto M., Hanyu T., Yoshio T., Matsuno H., Shimizu M., Murata N. “Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial”. Clin Exp Rheumatol 19:377-83, 2001. | ||
| In article | PubMed | ||
| [49] | Omata T., Itokazu Y., Inoue N., Segawa Y. “Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis”. Arzneimittelforschung 50, 148-53, 2005. | ||
| In article | |||
| [50] | Canapp S.O., Jr, McLaughlin R.M., Jr, Hoskinson J.J, Roush J.K., Butine M.D. “Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate”. Am J Vet Res 60, 1552-7, 1999. | ||
| In article | PubMed | ||
| [51] | Ronca F., Palmieri L., Panicucci P., Ronca G. “Anti-inflammatory activity of chondroitin sulfate”. Osteoarthritis Cartilage, 6 (Suppl A) 14-21, 1998. | ||
| In article | View Article | ||
| [52] | Verbruggen G., Veys E.M. “Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells” Acta Rhumatol Belg, 1 75-92, 1977. | ||
| In article | PubMed | ||
| [53] | Nishikawa N., Mori I., Umemoto J. “Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovial membrane”. Arch Biochem Biophys, 240, 146-153, 1985. | ||
| In article | View Article | ||
| [54] | Sawitzke A.D., Shi H., Finco M.F. “The effect of glucosamine and/or CS on the progression of knee OA a report from the glucosamine/chondroitin arthritis intervention trial.” Arthr. Rheum. 58(10), 3183-91, 2008. | ||
| In article | View Article PubMed | ||
| [55] | Monfort J., Pelletier J.P., Garcia-Giralt N. “Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues”. Ann Rheum Dis 67(6) 735-40, 2008. | ||
| In article | View Article PubMed | ||
| [56] | Sharma G., Saxena R.K., Mishra P. “Synergistic effects of chondroitin sulfate and cyclic pressurization on articular chondrocytes morphology and biochemical properties in alginate matrix”. Osteoarth. Cartil., 16, 1387-1394, 2008. | ||
| In article | View Article PubMed | ||
| [57] | Chan P.S., Caron J.P., Orth M.W. “Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions”. Am J Vet Res. 68(7) 709-15, 2007. | ||
| In article | View Article PubMed | ||
| [58] | Balazs E. “The physical properties of synovial fluid and the specific role of hyaluronic acid. In Disorders of the Knee. Edited by Helfet AJ. Philadelphia: J B Lippincott; 61-74, 1982. | ||
| In article | |||
| [59] | Lo G.H., LaValley M., McAlindon T. “Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis”. JAMA 290: 3115-21, 2003. | ||
| In article | View Article PubMed | ||
| [60] | Bannuru R.R., Natov N.S., Obadan I.E. “Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee OA: a systematic review and meta-analysis”. Arthri. Rheum 61, 1704-11, 2009. | ||
| In article | View Article PubMed | ||
| [61] | Ishijima M., Nakamura T., Shimizu K.. “Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial”. Arthritis Res. Therapy 16: R18, 2014. | ||
| In article | View Article PubMed | ||
| [62] | Jang J.D., Moon Y.S., Kim Y.S.. “Novel repair technique for articular cartilage defect using a fibrin and hyaluronic acid mixture” Tissue Engg Reg. Med. 10 (1) 1-9, 2013. | ||
| In article | View Article | ||
| [63] | Kim I.R.,Mauck R.L., Burdick J.A. “Hydrogel design for cartilage tissue engineering: A case study with hyaluronic acid” Biomaterials 32, 8771-82, 2011. | ||
| In article | View Article PubMed | ||
| [64] | Smith M.M., Ghosh P. “The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment” Rheumatol Int 7: 113-122, 1987. | ||
| In article | View Article PubMed | ||
| [65] | Pozo M.A., Balazs E.A., Belmonte C. “Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative”. Exp Brain Res. 116, 3-9, 1997. | ||
| In article | View Article PubMed | ||
| [66] | Belmonte C., Pozo M.A., Balazs E.A. “Modulation by hyaluronan and its derivatives (hylans) of sensory nerve activity signaling articular pain. In Chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives. Proceedings of the Wenner-Gren Foundation International Symposium. Edited by Laurent T. London: Portland Press; 205-217, 1998. | ||
| In article | |||
| [67] | Kawasaki K., Ochi M., Uchio Y., Adachi N., Matsusaki M. “Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels”. J Cell Physiol 179, 142-8, 1999. | ||
| In article | View Article | ||
| [68] | Ghosh P., Holbert C., Read R., Armstrong S. “Hyaluronic acid (hyaluronan) in experimental osteoarthritis”. J Rheumatol Suppl 43, 155-7, 1995. | ||
| In article | PubMed | ||
| [69] | Homandberg G.A., Hui F., Wen C., Kuettner K.E., Williams J.M. “Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: In vitro”. Osteoarthritis Cartilage 5:309-19, 1997. | ||
| In article | View Article | ||
| [70] | Kang Y., Eger W., Koepp H., Williams J.M., Kuettner K.E., Homandberg G.A. “Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteoglycan synthesis” J Orthop Res 17:858-69, 1999. | ||
| In article | View Article PubMed | ||
| [71] | Ogawa Y. “Immunolocalization of stromelysin, tumor factor (TNF) alpha, and TNF receptors in atrophied canine articular cartilage treated with hyaluronic acid and transforming growth factor beta”. Am J Vet Res 57, 1488-96, 1996. | ||
| In article | PubMed | ||
| [72] | Yasui T., Akatsuka M., Tobetto K., Umemoto J., Ando T., Yamashita K., Hayakawa T. “Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes”. Biomed Res 13, 343- 8, 1992. | ||
| In article | |||
| [73] | Nonaka T., Kikuchi H., Shimada W., Itagene H., Ikeda T., Hamanishi C., Tanaka S. “Effects of hyaluronic acid on fibrinolytic factors in the synovial fluid (in vivo). Pathophysiology 6:41-4, 1999(a). | ||
| In article | View Article | ||
| [74] | Tobetto K., Yasui T., Ando T., Hayaishi M., Motohashi N., Shinogi M., Mori I. “Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts”. Jpn J Pharmacol 60, 79-84, 1992. | ||
| In article | View Article PubMed | ||
| [75] | Yasui T., Akatsuka M., Tobetto K., Hayaishi M, Ando T. “The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin nE2 production in human osteoarthritic synovial cells”. Agents Actions 37, 155-6, 1999. | ||
| In article | View Article | ||
CiteULike
Mendeley
StumbleUpon
Delicious
Facebook
Twitter
LinkedIn
